missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Vimentin Antibody (VM452), Alexa Fluor™ 750, Novus Biologicals™
Mouse Monoclonal Antibody
Brand: Novus Biologicals NBP2-33060AF750
This item is not returnable.
View return policy
Description
Vimentin Monoclonal specifically detects Vimentin in Human, Porcine, Bovine, Canine, Chicken, Feline, Goat, Mouse (Negative), Rat (Negative) samples. It is validated for Western Blot, Flow Cytometry, Immunohistochemistry-Paraffin, Knockout Validated.
Specifications
| Vimentin | |
| Monoclonal | |
| Alexa Fluor 750 | |
| 50 mM sodium borate with 0.05% sodium azide | |
| VIM | |
| Recombinant full-length human vimentin protein (Uniprot: P08670) | |
| 0.1 mL | |
| 7431 | |
| Human, Pig, Bovine, Canine, Chicken, Feline, Goat, Mouse, Rat | |
| IgG1 κ |
| Western Blot, ELISA, Immunoassay | |
| VM452 | |
| Western Blot, ELISA, Knockout Validated | |
| FLJ36605, vimentin | |
| Mouse | |
| Protein A or G purified | |
| Primary | |
| This monoclonal antibody reacts with a 58kDa protein identified as Vimentin. It shows no cross-reaction with other closely related intermediate filament proteins (IFP however, when used in panels with other antibodies, it is useful for the sub-classification of a given tumor. Expression of Vimentin, when used in conjunction with anti-keratin, is helpful when distinguishing melanomas from undifferentiated carcinomas and large cell lymphomas. All melanomas and Schwannomas react strongly with anti-Vimentin. It labels a variety of mesenchymal cells, including melanocytes, lymphocytes, endothelial cells, and fibroblasts. Non-reactivity of anti-Vimentin is often considered more useful than its positive reactivity, since there are a few tumors that do not contain Vimentin, e.g. hepatoma and seminoma. Anti-Vimentin is also useful as a tissue process control reagent. | |
| Store at 4°C in the dark. |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction